4.6 Article

CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF--mTOR-HIF-1 signaling in patients with non-small cell lung cancer

Journal

ONCOIMMUNOLOGY
Volume 6, Issue 6, Pages -

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2017.1320011

Keywords

CD39; CD73; MDSCs; NSCLC; TGF-

Funding

  1. National Institutes of Health [CA149669, CA208354]
  2. National Natural Science Foundation of China [81171985, 81171986]
  3. Ministry of Public Health [20110110001]
  4. Basic and Advanced Technology Research Foundation from Science and Technology Department of Henan Province [112300410153, 122300410155]

Ask authors/readers for more resources

CD39/CD73-adenosine pathway has been recently defined as an important tumor-induced immunosuppressive mechanism. We here documented a fraction of CD11b(+)CD33(+) myeloid-derived suppressor cells (MDSCs) in peripheral blood and tumor tissues from non-small cell lung cancer (NSCLC) patients expressed surface ectonucleotidases CD39 and CD73. Tumor TGF- stimulated CD39 and CD73 expression, thereby inhibited T cell and NK cell activity, and protected tumor cells from the cytotoxic effect of chemotherapy through ectonucleotidase activity. Mechanistically, TGF- triggered phosphorylation of mammalian target of rapamycin, and subsequently activated hypoxia-inducible factor-1 (HIF-1) that induced CD39/CD73 expression on MDSCs. CD39 and CD73 on MDSCs, therefore, link their immunosuppressive and chemo-protective effects to NSCLC progression, providing novel targets for chemo-immunotherapeutic intervention.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available